Your session is about to expire
← Back to Search
ACP-204 30 mg for Alzheimer's Disease
Study Summary
This trial tests a drug for Alzheimer's Disease Prodromal (ADP) in 3 parts, evaluating safety, efficacy, and dose response.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Travel, including flights, are covered
Your expenses for travel tickets for this trial will be reimbursed.
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
Frequently Asked Questions
Is the elderly population being considered for enrollment in this investigation?
"According to the prerequisites listed for this clinical trial, those aged between 55 and 95 years old are eligible. There are 136 trials that accept applicants under 18 while 809 permit individuals over 65 to participate."
What criteria must be satisfied for potential participants in this clinical research?
"The researchers of this clinical trial are seeking 1074 individuals between the ages of 55 and 95 that suffer from Alzheimer's disease. All applicants must meet these criteria in order to be accepted into the study."
How many participants are receiving treatment in this experiment?
"Affirmative, the data accessible on clinicaltrials.gov shows that this research endeavor is presently recruiting patients. The study was inaugurated on November 14th 2023 and its information has been updated most recently on 11/27/2023. A total of 1074 participants are needed at 1 medical centre for participation in the investigation."
Is this investigation actively recruiting participants?
"Affirmative. According to clinicaltrials.gov, this medical trial is still actively recruiting new participants and has been since November 14th 2023 - the day of its initial posting. The study requires 1074 patients from a single site for completion."
Share this study with friends
Copy Link
Messenger